Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2014-11-21 Regulatory Filings
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings
2014-11-21 English
425B5
Capital/Financing Update Classification · 95% confidence The document is a Form 424B5 prospectus filed pursuant to Rule 424(b)(3) with the SEC. It is a registration statement prospectus related to the resale of shares by a selling stockholder, describing the terms of the offering, the selling stockholder, plan of distribution, risk factors, and company business overview. It is not a financial report, earnings release, or management discussion. The document is a detailed prospectus for a securities offering, which fits the category of Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes through a registered offering of shares. The document length is substantial (15,000 characters) and contains the full prospectus text, not just an announcement or link to a report, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2014-11-20 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus for a common stock offering filed pursuant to Rule 424(b)(5). It includes information about the offering terms, risk factors, use of proceeds, and company overview. The document references a registration statement and is clearly a capital raising filing. It is not a financial report, earnings release, management discussion, or any other report type. It is a disclosure related to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2014-11-20 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a purchase agreement with Lincoln Park Capital Fund for the sale of common stock. It details the terms of the agreement, including the amount, pricing, and conditions. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a capital raising agreement and financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 6777 characters, which is sufficient to be the actual filing, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2014-11-20 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a correspondence related to a securities offering registration, not a financial report or detailed filing. The document length is short (1879 characters) and it does not contain financial data or report content. It is an announcement/request related to a regulatory filing process. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2014-11-19 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is the announcement of the termination of an executive officer, specifically the Executive Vice President and Chief Medical Officer. This fits the category of announcements related to changes in the company's board of directors or senior management. The document does not contain financial data, audit information, or other report types. Therefore, it should be classified as Board/Management Information (MANG). The document length is short and focused on management change, confirming this classification.
2014-11-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.